ZhenGe Biotech, a Chinese macromolecular pharmaceutical contract development and manufacturing organisation (CDMO), has secured $51 million in a Series A round of financing led by Shanghai-based healthcare investment firm LYFE Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
